Last $14.35 USD
Change Today +0.62 / 4.52%
Volume 226.8K
OMER On Other Exchanges
Symbol
Exchange
NASDAQ GM
Berlin
As of 4:00 PM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

201 Elliott Avenue West

Seattle, WA 98119

United States

Phone: 206-676-5000

Fax: 206-676-5005

Is in OMS201 are contained in generic, FDA-approved drugs that have been marketed in the United States. PDE10 Program – OMS824 Phosphodiesterase 10, or PDE10, is an enzyme that is expressed in areas of the brain strongly linked to diseases that affect cognition, including schizophrenia and Huntington’s disease. The company’s proprietary compound OMS824 inhibits PDE10 and is being developed for the treatment of cognitive disorders, including schizophrenia where OMS824 may have a beneficial effect on the positive (e.g., hallucinations), negative (e.g., flat affect) and cognitive symptoms of the disease. PPARg Program – OMS405 In its peroxisome proliferator-activated receptor gamma, or PPARg, program, the company is in the process of developing proprietary compositions that include PPARg agonists for the treatment and prevention of addiction to substances of abuse, which may include opioids, nicotine and alcohol. The company’s collaborators at The New York State Psychiatric Institute are conducting two Phase 2 clinical trials for its PPARg program. These studies are evaluating a PPARg agonist, alone or in combination with other agents, for treatment of addiction to opioids and to nicotine. The National Institute on Drug Abuse is providing substantially all of the funding for these clinical trials. Intellectual Property As of February 15, 2013, the company owned or held worldwide exclusive licenses to a total of 41 issued or allowed patents and 51 pending patent applications in the United States and 167 issued or allowed patents and 163 pending patent applications in foreign markets directed to therapeutic compositions and methods related to its development programs. As of February 15, 2013, its patent portfolio included 17 U.S. and 67 foreign issued or allowed patents, and 8 U.S. and 19 foreign pending patent applications, directed to its PharmacoSurgery products and development programs. Research and Development The company has built a research and development organization that includes expertise in discovery research, preclinical development, product formulation, analytical and medicinal chemistry, manufacturing, clinical development and regulatory and quality assurance. Its research and development expenses were $31.9 million in 2012. Regulation In the United States, the company’s products are regulated by the FDA as drugs or biologics under the Federal Food, Drug, and Cosmetic Act and implementing regulations and, in the case of biologics, also under the Public Health Service Act. Before its products may be marketed in the United States, each must be approved by the FDA. History Omeros Corporation was founded in 1994.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OMER:US $14.35 USD +0.62

OMER Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OMER.
View Industry Companies
 

Industry Analysis

OMER

Industry Average

Valuation OMER Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 701.2x
Price/Book 89.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 630.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OMEROS CORP, please visit www.omeros.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.